On November 18, Kangfang Biotech and Iwasi's overseas partner Summit Therapeutics jointly announced that Kangfang Biotech's global first tumor immunity 2.0 cornerstone drug, evasil contrast valiumab, as a consolidation treatment for locally advanced, unresectable non-small cell lung cancer with no disease progression after receiving radical platinum-containing simultaneous chemoradiotherapy, has begun an international multi-center registration phase III study.

Zhitongcaijing · 2d ago
On November 18, Kangfang Biotech and Iwasi's overseas partner Summit Therapeutics jointly announced that Kangfang Biotech's global first tumor immunity 2.0 cornerstone drug, evasil contrast valiumab, as a consolidation treatment for locally advanced, unresectable non-small cell lung cancer with no disease progression after receiving radical platinum-containing simultaneous chemoradiotherapy, has begun an international multi-center registration phase III study.